<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Clostridioides difficile Infection - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
            --banner-bg: #fef3c7;
            --banner-border: #f59e0b;
            --banner-text: #92400e;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .notice-banner {
            background: var(--banner-bg);
            color: var(--banner-text);
            border-bottom: 1px solid var(--banner-border);
            padding: 12px 16px;
            text-align: center;
            font-size: 0.95rem;
            cursor: pointer;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "‚Ü≥ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    <div class="notice-banner" role="button" tabindex="0">This resource is in its pre-alpha development stage. Content is actively being curated and may be incomplete or subject to change.</div>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Clostridioides difficile Infection</span>
        </nav>

        <header class="page-header">
            <h1>Clostridioides difficile Infection</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Infectious</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0000705" target="_blank">
                        MONDO:0000705
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Infectious colitis</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Healthcare-associated infections</span>
                
            </div>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">10</div>
                <div class="stat-label">Pathophysiology</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">8</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Genes</div>
            </div>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#subtypes">
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Subtypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#differentials">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Differentials</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#datasets">
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Datasets</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#trials">
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Trials</div>
            </div>
            </a>
            
        </div>

        <!-- Classifications -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üè∑</div>
                <h2 class="card-title">Classifications</h2>
            </div>
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">Harrison's Chapter</div>
                <div class="tag-list">
                    
                    <span class="tag tag-classification">infectious disease</span>
                    
                    <span class="tag tag-classification">bacterial infectious disease</span>
                    
                </div>
            </div>
            
            
            
            
            
            
        </div>
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        
        <div class="card" id="subtypes">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">‚óÜ</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">3</span>
            </div>
            
            
            
                
                
                    
                
                
            
                
                
                
            
                
                
                
            
            
                
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Acute Clostridioides difficile infection
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">First-episode CDI with manifestations ranging from uncomplicated antibiotic-associated diarrhea to severe fulminant colitis.
</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28613708" target="_blank">PMID:28613708</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"C difficile infections can range from an asymptomatic carrier to diarrhea, progressing to severe conditions such as pseudomembranous colitis and toxic megacolon with septic shock, often resulting in a high mortality rate."</div>
                
                
                <div class="evidence-explanation">Supports a broad acute disease spectrum from mild to fulminant presentation.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Recurrent Clostridioides difficile infection
                        
                    </div>
                    <div class="subtype-meta">
                        
                        <span class="subtype-freq-badge">up to 25%</span>
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Recurrent CDI (rCDI) following initial treatment, typically occurring in the early post-antibiotic period and representing a major clinical subtype.
</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1177/20503121241274192" target="_blank">DOI:10.1177/20503121241274192</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Up to 25% of patients with an initial CDI episode will experience recurrent CDI (rCDI), which most commonly occurs in the first 8 weeks following antibiotic therapy."</div>
                
                
                <div class="evidence-explanation">Provides explicit frequency and timing evidence for the recurrent subtype.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Non-colitic C. difficile infection (carrier state or diarrheal disease)
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Infection states without overt colitis, including asymptomatic carriage and diarrheal presentations that do not progress to severe colonic inflammation.
</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28613708" target="_blank">PMID:28613708</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"C difficile infections can range from an asymptomatic carrier to diarrhea, progressing to severe conditions such as pseudomembranous colitis and toxic megacolon with septic shock, often resulting in a high mortality rate."</div>
                
                
                <div class="evidence-explanation">Explicitly supports CDI forms that precede or occur without severe colitis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
            
        </div>
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">10</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Antibiotic-Induced Microbial Depletion</div>
                
                <div class="item-desc">Broad-spectrum antibiotics (especially fluoroquinolones, clindamycin, cephalosporins) cause indiscriminate killing of gut commensals, dramatically reducing microbial diversity and biomass. This creates ecological opportunity for C. difficile colonization.
</div>
                
                
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        colon
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0001155" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28613708" target="_blank">PMID:28613708</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The most significant risk factor for C difficile infection is broad-spectrum antibiotics. Patients can be colonized with C difficile without symptoms, but antibiotic use disturbs the balance of gut flora, enabling C difficile overgrowth and infection."</div>
                
                
                <div class="evidence-explanation">StatPearls notes antibiotic-driven dysbiosis allows C. difficile overgrowth in the colon.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Loss of Colonization Resistance</div>
                
                <div class="item-desc">The healthy microbiome normally prevents C. difficile colonization through multiple mechanisms: nutrient competition (especially for proline, amino acids), niche exclusion, and production of bacteriocins and antimicrobial peptides. Antibiotic disruption removes these competitive barriers.
</div>
                
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26185088" target="_blank">PMID:26185088</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"A general feature of a normal, healthy gut microbiota can generate conditions in the gut that disfavor colonization of enteric pathogens. This is termed colonization-resistance (CR). Upon disturbance of the microbiota, CR can be transiently disrupted, and pathogens can gain the opportunity to..."</div>
                
                
                <div class="evidence-explanation">Review describes colonization resistance as a key protective function lost during antibiotic-induced dysbiosis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40366862" target="_blank">PMID:40366862</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The gut microbiota in the Control group showed higher Chao1 index (p &lt; 0.05)... Collinsella_aerofaciens, Collinsella_sp_4_8_47FAA, Collinsella_tanakaei and Collinsella_sp_CAG_166 were enriched in Control."</div>
                
                
                <div class="evidence-explanation">Metagenomic study confirms CDI patients have reduced diversity and depletion of protective Collinsella species compared to healthy controls.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Loss of Secondary Bile Acid Production</div>
                
                <div class="item-desc">Loss of bile acid 7Œ±-dehydroxylating bacteria (Clostridium scindens, C. hylemonae, and related taxa) prevents conversion of primary bile acids (cholate, chenodeoxycholate) to secondary bile acids (deoxycholate, lithocholate). Primary bile acids promote C. difficile spore germination; secondary bile acids inhibit both germination and vegetative growth.
</div>
                
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32179626" target="_blank">PMID:32179626</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-IN_VITRO">In Vitro</span>
                    
                </div>
                
                <div class="evidence-snippet">"Inhibition of C. difficile by commensals correlated with the efficient conversion of cholate to deoxycholate, a secondary bile acid that inhibits C. difficile germination, growth, and toxin production."</div>
                
                
                <div class="evidence-explanation">Study shows bile acid conversion by bai operon-carrying bacteria is key to C. difficile inhibition.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28066726" target="_blank">PMID:28066726</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"Amendment of Oligo-MM12 with C. scindens normalized the large intestinal bile acid composition by reconstituting 7Œ±-dehydroxylation. These changes had only minor effects on the composition of the native Oligo-MM12, but significantly decreased early large intestinal C. difficile colonization and..."</div>
                
                
                <div class="evidence-explanation">Gnotobiotic mouse study demonstrates C. scindens provides colonization resistance through bile acid metabolism.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Bile Acid-Mediated TcdB Buffering Failure</div>
                
                <div class="item-desc">Intestinal bile acids can directly buffer TcdB cytotoxicity. When bile-acid buffering is reduced or toxin burden is high, this protection is overcome and toxin-mediated epithelial injury proceeds.
</div>
                
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37126691" target="_blank">PMID:37126691</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-IN_VITRO">In Vitro</span>
                    
                </div>
                
                <div class="evidence-snippet">"Small molecules extracted from the lumenal contents of the small intestine, cecum, colon, and feces were found to inhibit TcdB in accordance with the differential amounts of total bile acids in each compartment."</div>
                
                
                <div class="evidence-explanation">Supports direct bile-acid inhibition of TcdB as a mechanistic modifier of severity.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">C. difficile Germination and Expansion</div>
                
                <div class="item-desc">C. difficile spores germinate in the favorable environment created by antibiotic disruption: available nutrients (especially proline), primary bile acids, and lack of competition. Vegetative cells proliferate to high density, occupying the ecological niche vacated by commensals.
</div>
                
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28613708" target="_blank">PMID:28613708</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Patients can be colonized with C difficile without symptoms, but antibiotic use disturbs the balance of gut flora, enabling C difficile overgrowth and infection."</div>
                
                
                <div class="evidence-explanation">Antibiotic-disrupted environment permits C. difficile overgrowth from spore to vegetative form.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Toxin Production (TcdA/TcdB)</div>
                
                <div class="item-desc">C. difficile secretes two large clostridial glucosylating toxins: TcdA (enterotoxin, 308 kDa) and TcdB (cytotoxin, 270 kDa). Both are glucosyltransferases that inactivate Rho family GTPases (Rho, Rac, Cdc42) by monoglucosylation of a critical threonine residue, disrupting the actin cytoskeleton.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Pathogenesis
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0009405" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15831824" target="_blank">PMID:15831824</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Following expression and release from the bacterium, TcdA and TcdB translocate to the cytosol of target cells and inactivate small GTP-binding proteins, which include Rho, Rac, and Cdc42. Inactivation of these substrates occurs through monoglucosylation of a single reactive threonine."</div>
                
                
                <div class="evidence-explanation">Comprehensive review details the molecular mechanism of toxin action on Rho GTPases.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34837014" target="_blank">PMID:34837014</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The bacterium produces up to three toxins, which are considered the major virulence factors in C. difficile infection. These toxins promote inflammation, tissue damage and diarrhoea."</div>
                
                
                <div class="evidence-explanation">Review confirms toxins as major virulence factors causing disease pathology.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Epithelial Cell Death and Barrier Disruption</div>
                
                <div class="item-desc">Toxin-mediated Rho GTPase inactivation causes actin cytoskeleton condensation, loss of cell-cell junctions, and epithelial cell rounding followed by death. This creates gaps in the epithelial barrier, exposing the lamina propria to luminal contents.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Colonic Epithelial Cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0011108" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15831824" target="_blank">PMID:15831824</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"By glucosylating small GTPases, TcdA and TcdB cause actin condensation and cell rounding, which is followed by death of the cell."</div>
                
                
                <div class="evidence-explanation">Review describes the cellular consequences of toxin-mediated GTPase inactivation.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Binary Toxin (CDT)-Associated Inflammatory Signaling</div>
                
                <div class="item-desc">In CDT-positive strains, the binary toxin axis can activate inflammasome-linked inflammatory pathways in myeloid cells and increase early disease severity.
</div>
                
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39298531" target="_blank">PMID:39298531</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-IN_VITRO">In Vitro</span>
                    
                </div>
                
                <div class="evidence-snippet">"Besides producing the main virulence factors, toxin A (TcdA) and toxin B (TcdB), many of the common clinical strains encode the C. difficile transferase (CDT) binary toxin."</div>
                
                
                <div class="evidence-explanation">Documents the presence of CDT among common clinical strains and supports including a CDT-specific mechanism node.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Neutrophil Recruitment and Inflammation</div>
                
                <div class="item-desc">TcdA triggers IL-8 and other chemokine release from epithelial cells, causing massive neutrophil influx into the colonic mucosa. Neutrophils form the characteristic &#34;volcano lesions&#34; and contribute to tissue damage through degranulation, reactive oxygen species, and NET formation.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Neutrophil
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000775" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Inflammatory Response
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006954" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15831824" target="_blank">PMID:15831824</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Furthermore, there have been major advances in defining the role of these toxins in modulating the inflammatory events involving the disruption of cell junctions, neuronal activation, cytokine production, and infiltration by polymorphonuclear cells."</div>
                
                
                <div class="evidence-explanation">Review details toxin-induced inflammatory cascade including neutrophil recruitment.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Pseudomembranous Colitis</div>
                
                <div class="item-desc">Characteristic raised yellow-white plaques on colonic mucosa composed of fibrin, mucus, neutrophils, and cellular debris overlying areas of epithelial necrosis. Represents severe C. difficile infection with high morbidity. Fluid secretion and diarrhea result from barrier loss and inflammation.
</div>
                
                
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        colon
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0001155" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34837014" target="_blank">PMID:34837014</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"These toxins promote inflammation, tissue damage and diarrhoea."</div>
                
                
                <div class="evidence-explanation">Toxin activity drives the pseudomembrane-associated inflammation and diarrheal fluid loss that characterize severe CDI.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">‚¨°</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph LR
    Loss_of_Secondary_Bile_Acid_Production[&#34;Loss of Secondary Bile Acid Production&#34;]
    Neutrophil_Recruitment_and_Inflammation[&#34;Neutrophil Recruitment and Inflammation&#34;]
    C._difficile_Germination_and_Expansion[&#34;C. difficile Germination and Expansion&#34;]
    Pseudomembranous_Colitis[&#34;Pseudomembranous Colitis&#34;]
    Epithelial_Cell_Death_and_Barrier_Disruption[&#34;Epithelial Cell Death and Barrier Disruption&#34;]
    Loss_of_Colonization_Resistance[&#34;Loss of Colonization Resistance&#34;]
    Toxin_Production_TcdA_TcdB[&#34;Toxin Production (TcdA/TcdB)&#34;]
    Binary_Toxin_CDT_Associated_Inflammatory_Signaling[&#34;Binary Toxin (CDT)-Associated Inflammatory Signaling&#34;]
    Antibiotic_Induced_Microbial_Depletion[&#34;Antibiotic-Induced Microbial Depletion&#34;]
    Bile_Acid_Mediated_TcdB_Buffering_Failure[&#34;Bile Acid-Mediated TcdB Buffering Failure&#34;]

    Antibiotic_Induced_Microbial_Depletion --&gt; Loss_of_Colonization_Resistance
    Antibiotic_Induced_Microbial_Depletion --&gt; Loss_of_Secondary_Bile_Acid_Production
    Loss_of_Colonization_Resistance --&gt; C._difficile_Germination_and_Expansion
    Loss_of_Secondary_Bile_Acid_Production --&gt; C._difficile_Germination_and_Expansion
    Bile_Acid_Mediated_TcdB_Buffering_Failure --&gt; Epithelial_Cell_Death_and_Barrier_Disruption
    C._difficile_Germination_and_Expansion --&gt; Toxin_Production_TcdA_TcdB
    Toxin_Production_TcdA_TcdB --&gt; Epithelial_Cell_Death_and_Barrier_Disruption
    Toxin_Production_TcdA_TcdB --&gt; Neutrophil_Recruitment_and_Inflammation
    Toxin_Production_TcdA_TcdB --&gt; Binary_Toxin_CDT_Associated_Inflammatory_Signaling
    Epithelial_Cell_Death_and_Barrier_Disruption --&gt; Pseudomembranous_Colitis
    Binary_Toxin_CDT_Associated_Inflammatory_Signaling --&gt; Neutrophil_Recruitment_and_Inflammation
    Neutrophil_Recruitment_and_Inflammation --&gt; Pseudomembranous_Colitis

    style Loss_of_Secondary_Bile_Acid_Production fill:#dbeafe
    style Neutrophil_Recruitment_and_Inflammation fill:#dbeafe
    style C._difficile_Germination_and_Expansion fill:#dbeafe
    style Pseudomembranous_Colitis fill:#dbeafe
    style Epithelial_Cell_Death_and_Barrier_Disruption fill:#dbeafe
    style Loss_of_Colonization_Resistance fill:#dbeafe
    style Toxin_Production_TcdA_TcdB fill:#dbeafe
    style Binary_Toxin_CDT_Associated_Inflammatory_Signaling fill:#dbeafe
    style Antibiotic_Induced_Microbial_Depletion fill:#dbeafe
    style Bile_Acid_Mediated_TcdB_Buffering_Failure fill:#dbeafe</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">8</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Cardiovascular<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Digestive<span class="pill-count">(4)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-3">Metabolism<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-4">Constitutional<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-5">Other<span class="pill-count">(1)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Cardiovascular
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Septic shock
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0031273" target="_blank">
                                Shock
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0031273)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28613708" target="_blank">PMID:28613708</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"C difficile infections can range from an asymptomatic carrier to diarrhea, progressing to severe conditions such as pseudomembranous colitis and toxic megacolon with septic shock, often resulting in a high mortality rate."</div>
                
                
                <div class="evidence-explanation">Supports septic shock as a life-threatening complication in severe CDI.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Digestive
                    <span class="cat-count">4</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Diarrhea
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002014" target="_blank">
                                Diarrhea
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002014)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28613708" target="_blank">PMID:28613708</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"This obligate anaerobic bacillus is recognized for its ability to produce toxins and is the leading cause of antibiotic-associated diarrhea worldwide."</div>
                
                
                <div class="evidence-explanation">StatPearls review states CDI is the leading cause of antibiotic-associated diarrhea.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Nausea
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002018" target="_blank">
                                Nausea
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002018)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33402156" target="_blank">PMID:33402156</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"A 53-year-old Caucasian male presented to the emergency room for two days of lower abdominal pain associated with nausea, non-bilious vomiting, and subjective fevers."</div>
                
                
                <div class="evidence-explanation">Case report documents nausea among presenting symptoms in laboratory-confirmed CDI.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Vomiting
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002013" target="_blank">
                                Vomiting
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002013)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33402156" target="_blank">PMID:33402156</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"A 53-year-old Caucasian male presented to the emergency room for two days of lower abdominal pain associated with nausea, non-bilious vomiting, and subjective fevers."</div>
                
                
                <div class="evidence-explanation">Case report documents vomiting as part of CDI clinical presentation.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Toxic megacolon
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_6000852" target="_blank">
                                Megacolon
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:6000852)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28613708" target="_blank">PMID:28613708</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"C difficile infections can range from an asymptomatic carrier to diarrhea, progressing to severe conditions such as pseudomembranous colitis and toxic megacolon with septic shock, often resulting in a high mortality rate."</div>
                
                
                <div class="evidence-explanation">Supports toxic megacolon as a severe, high-risk complication of CDI.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-3">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Metabolism
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Fever
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001945" target="_blank">
                                Fever
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001945)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33402156" target="_blank">PMID:33402156</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"A 53-year-old Caucasian male presented to the emergency room for two days of lower abdominal pain associated with nausea, non-bilious vomiting, and subjective fevers."</div>
                
                
                <div class="evidence-explanation">CDI case report documents fever accompanying infection.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-4">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Constitutional
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Abdominal pain
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002027" target="_blank">
                                Abdominal pain
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002027)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37004449" target="_blank">PMID:37004449</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"A 40 years old male patient presented with abdominal pain and diarrhea of 10 days duration after he was diagnosed and managed as a case of Clostridium Difficile infection and amebiasis."</div>
                
                
                <div class="evidence-explanation">Case report notes abdominal pain with CDI presentation.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-5">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Other
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Pseudomembranous colitis
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002583" target="_blank">
                                Colitis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002583)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28613708" target="_blank">PMID:28613708</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"C difficile infections can range from an asymptomatic carrier to diarrhea, progressing to severe conditions such as pseudomembranous colitis and toxic megacolon with septic shock, often resulting in a high mortality rate."</div>
                
                
                <div class="evidence-explanation">Explicitly identifies pseudomembranous colitis as a severe CDI manifestation.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Vancomycin
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Oral vancomycin is first-line treatment for C. difficile infection.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38508330" target="_blank">PMID:38508330</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Effective infection management requires appropriate interpretation of diagnostic tests, as well as the use of vancomycin and fidaxomicin as first-line treatment."</div>
                
                
                <div class="evidence-explanation">Clinical review lists oral vancomycin among first-line agents for CDI management.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Fidaxomicin
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Alternative antibiotic with lower recurrence rates.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38726585" target="_blank">PMID:38726585</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"IDSA/SHEA shifted its preference for initial treatment to fidaxomicin over vancomycin and metronidazole due to its lower recurrence rate."</div>
                
                
                <div class="evidence-explanation">Guideline update highlights fidaxomicin as preferred initial therapy because of reduced recurrence.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39282548" target="_blank">PMID:39282548</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Management of CDI has evolved, with fidaxomicin emerging as a superior treatment option over vancomycin for initial and recurrent infections due to its reduction of recurrence rate."</div>
                
                
                <div class="evidence-explanation">Recent review reinforces fidaxomicin&#39;s superiority to vancomycin for initial and recurrent CDI.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Fecal microbiota transplantation
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000748" target="_blank">
                            MAXO:0000748
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Restoration of normal gut microbiota for recurrent infections.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38508330" target="_blank">PMID:38508330</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Novel treatments such as Bezlotoxumab, fecal microbiota transplant, and live biotherapeutic products are proven effective in recurrent C. difficile infection and address dysbiosis."</div>
                
                
                <div class="evidence-explanation">Review notes FMT as effective for recurrent CDI in restoring microbiota.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39282548" target="_blank">PMID:39282548</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Faecal microbiota transplantation (FMT) is effective for recurrent CDI, restoring gut eubiosis."</div>
                
                
                <div class="evidence-explanation">Update article explicitly states FMT effectiveness for recurrent CDI by reestablishing gut balance.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Bezlotoxumab
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Monoclonal antibody against toxin B to prevent CDI recurrence when added to standard therapy.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39282548" target="_blank">PMID:39282548</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Bezlotoxumab, a monoclonal antibody against C. difficile toxin B, has shown promise in reducing recurrence rates."</div>
                
                
                <div class="evidence-explanation">Review notes bezlotoxumab reduces CDI recurrence when used adjunctively with standard antibiotics.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Loop ileostomy with colonic lavage
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000004" target="_blank">
                            MAXO:0000004
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Organ-preserving surgical approach for fulminant CDI when medical therapy fails.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39650985" target="_blank">PMID:39650985</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In cases where pharmacological management has been ineffective, fecal microbiota transplantation and surgical intervention demonstrated success."</div>
                
                
                <div class="evidence-explanation">Case report highlights loop ileostomy with lavage as a surgical option after failed pharmacologic therapy in fulminant CDI.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ccfbf1; color: #0d9488;">üåç</div>
                <h2 class="card-title">Environmental Factors</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Healthcare facility exposure</div>
                
                
                <div class="item-desc">Hospital environments facilitate C. difficile spore persistence and transmission, underpinning healthcare-associated CDI.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28613708" target="_blank">PMID:28613708</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Contaminated surfaces and medical equipment in healthcare facilities can become reservoirs for C difficile spores, potentially transmitting to patients if proper cleaning protocols are not routinely implemented."</div>
                
                
                <div class="evidence-explanation">Review notes hospital environmental reservoirs drive healthcare-associated CDI transmission.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Biochemical Markers -->
        

        <!-- Differential Diagnoses -->
        
        <div class="card" id="differentials">
            <div class="card-header">
                <div class="card-icon" style="background: #fef2f2; color: #dc2626;">üîÄ</div>
                <h2 class="card-title">Differential Diagnoses</h2>
                <span class="card-count">5</span>
            </div>
            <p style="margin-bottom: 16px; font-size: 0.95rem; color: var(--text-muted);">
                Conditions with similar clinical presentations that must be differentiated from Clostridioides difficile Infection:
            </p>
            
            <div class="item-box differential-box">
                <div class="item-name">
                    Ulcerative colitis
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/MONDO_0005101" target="_blank">
                            MONDO:0005101
                        </a>
                    </span>
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    Chronic immune-mediated colitis that can flare with bloody diarrhea and may coexist with CDI.
                </div>
                
                
                <div class="differential-distinctions">
                    <strong>Distinguishing Features</strong>
                    
                    <ul>
                        
                        <li>Continuous colonic inflammation from rectum proximally on endoscopy.</li>
                        
                        <li>Bloody mucus stools and chronic course with flares.</li>
                        
                        <li>Histology shows crypt architectural distortion and chronic inflammatory infiltrate.</li>
                        
                    </ul>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38335423" target="_blank">PMID:38335423</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"This case underscores the diagnosis of severe UC through colonoscopy and colonic biopsy, along with the supplementary identification of a positive result for Clostridioides difficile in the fecal sample."</div>
                
                
                <div class="evidence-explanation">Report highlights overlapping presentation of UC flare with concurrent CDI.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box differential-box">
                <div class="item-name">
                    Lymphocytic colitis
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/MONDO_0000704" target="_blank">
                            MONDO:0000704
                        </a>
                    </span>
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    Microscopic colitis subtype causing chronic watery diarrhea that can mimic or coexist with CDI.
                </div>
                
                
                <div class="differential-distinctions">
                    <strong>Distinguishing Features</strong>
                    
                    <ul>
                        
                        <li>Chronic watery diarrhea with normal endoscopic appearance.</li>
                        
                        <li>Biopsy reveals increased intraepithelial lymphocytes without ulceration.</li>
                        
                    </ul>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38313897" target="_blank">PMID:38313897</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Persistent watery diarrhea and was diagnosed with lymphocytic colitis in the setting of a concomitant C. difficile infection."</div>
                
                
                <div class="evidence-explanation">Case shows lymphocytic colitis presenting with CDI-like diarrhea.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box differential-box">
                <div class="item-name">
                    Ischemic colitis
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/MONDO_0000701" target="_blank">
                            MONDO:0000701
                        </a>
                    </span>
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    Colonic ischemia presenting with acute abdominal pain and diarrhea that can be confused with infectious colitis.
                </div>
                
                
                <div class="differential-distinctions">
                    <strong>Distinguishing Features</strong>
                    
                    <ul>
                        
                        <li>Sudden crampy abdominal pain with segmental ischemic changes on imaging/endoscopy.</li>
                        
                        <li>Often hematochezia and disproportionate pain relative to diarrhea volume.</li>
                        
                    </ul>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37004449" target="_blank">PMID:37004449</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"A 40 years old male patient presented with abdominal pain and diarrhea of 10 days duration after he was diagnosed and managed as a case of Clostridium Difficile infection and amebiasis; computed tomography angiography revealed a vascular malformation ... he underwent Hartmann&#39;s procedure due to..."</div>
                
                
                <div class="evidence-explanation">Case documents ischemic colitis occurring in the context of CDI symptoms.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box differential-box">
                <div class="item-name">
                    Strongyloidiasis hyperinfection
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/MONDO_0005974" target="_blank">
                            MONDO:0005974
                        </a>
                    </span>
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    Parasitic hyperinfection that can present with diarrhea and mimic severe CDI in immunosuppressed hosts.
                </div>
                
                
                <div class="differential-distinctions">
                    <strong>Distinguishing Features</strong>
                    
                    <ul>
                        
                        <li>Occurs in immunosuppressed patients (e.g., prolonged steroids) with disseminated larvae.</li>
                        
                        <li>Larvae detectable in stool, sputum, or bronchoalveolar lavage; eosinophilia may be absent.</li>
                        
                    </ul>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35181536" target="_blank">PMID:35181536</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"We describe a fatal case of S. stercoralis hyperinfection ... presenting with diarrhea along with Clostridium difficile colitis after the use of a prolonged course of steroids."</div>
                
                
                <div class="evidence-explanation">Report shows Strongyloides hyperinfection mimicking CDI in steroid-treated patient.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box differential-box">
                <div class="item-name">
                    Acute appendicitis
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/MONDO_0005649" target="_blank">
                            MONDO:0005649
                        </a>
                    </span>
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    Extraintestinal manifestation with right lower quadrant pain that can coexist with or be mistaken for CDI.
                </div>
                
                
                <div class="differential-distinctions">
                    <strong>Distinguishing Features</strong>
                    
                    <ul>
                        
                        <li>Localized right lower quadrant tenderness with rebound/guarding.</li>
                        
                        <li>CT shows appendiceal enlargement and wall thickening; diarrhea often absent or minimal.</li>
                        
                    </ul>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33402156" target="_blank">PMID:33402156</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Repeat CT of the abdomen and pelvis with contrast (Fig. 1) was performed which showed progression of his colitis, now extending from the cecum to the rectum as well as findings concerning for appendicitis as seen on the prior CT scan. C. difficile testing was positive for which the patient was..."</div>
                
                
                <div class="evidence-explanation">Case report documents appendicitis identified alongside CDI with CT progression guiding management.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Datasets -->
        
        <div class="card" id="datasets">
            <div class="card-header">
                <div class="card-icon" style="background: #e0f2fe; color: #0284c7;">üìä</div>
                <h2 class="card-title">Related Datasets</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box dataset-box">
                <div class="item-name">
                    Metagenomic, metabolomic, and lipidomic shifts associated with fecal microbiota transplantation for recurrent CDI
                    
                    <span class="dataset-accession">
                        <a href="https://www.ncbi.nlm.nih.gov/sra/PRJNA1055134" target="_blank">sra:PRJNA1055134</a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Longitudinal stool multi-omics dataset from recurrent CDI patients sampled before and after successful FMT, used to profile microbiome, lipidome, and metabolome restructuring associated with recurrence prevention.</div>
                
                <div class="item-meta">
                    
                    <span class="tag tag-organism">human</span>
                    
                    
                    <span class="tag tag-datatype">METABOLOMICS</span>
                    
                    
                    <span class="tag tag-dataset">n=14</span>
                    
                    
                </div>
                
                
                <div class="item-meta" style="margin-top: 6px;">
                    <strong style="font-size: 0.8rem; color: #0369a1;">Conditions:</strong>
                    
                    <span class="tag" style="background: #f0f9ff; color: #0369a1; font-size: 0.8rem;">recurrent CDI pre-FMT</span>
                    
                    <span class="tag" style="background: #f0f9ff; color: #0369a1; font-size: 0.8rem;">recurrent CDI post-FMT</span>
                    
                </div>
                
                
                
    
    
                
                <div style="margin-top: 8px; font-size: 0.85rem;">
                    <a href="http://www.ncbi.nlm.nih.gov/pubmed/39377587" target="_blank" style="color: var(--secondary);">PMID:39377587</a>
                </div>
                
                
                <div class="item-desc" style="margin-top: 8px; font-style: italic;">Public sequencing reads are deposited under BioProject PRJNA1055134 (reported in the article&#39;s data-availability section).
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39377587" target="_blank">PMID:39377587</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Here, we use longitudinal stool samples collected from patients undergoing FMT to evaluate intra-individual changes in the microbiome, metabolome, and lipidome after successful FMTs relative to their baselines pre-FMT."</div>
                
                
                <div class="evidence-explanation">Describes the core study design and rationale represented in this rCDI dataset.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Clinical Trials -->
        
        <div class="card" id="trials">
            <div class="card-header">
                <div class="card-icon" style="background: #f5f3ff; color: #a855f7;">üî¨</div>
                <h2 class="card-title">Clinical Trials</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box clinical-trial-box">
                <div class="item-name">
                    NCT03183128
                    
                    <span class="tag tag-phase">PHASE_III</span>
                    
                    
                    <span class="tag tag-status">COMPLETED</span>
                    
                </div>
                
                <div class="item-desc">ECOSPOR III trial evaluating oral SER-109 versus placebo after standard-of-care antibiotics to prevent recurrent CDI.
</div>
                
                
                <div class="item-meta">
                    <strong style="font-size: 0.8rem; color: #6b21a8;">Target Phenotypes:</strong>
                    
                    <span class="tag" style="background: #ede9fe; color: #6b21a8; font-size: 0.8rem;">
                        Diarrhea
                        
                        <a href="http://purl.obolibrary.org/obo/HP_0002014" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://clinicaltrials.gov/study/NCT03183128" target="_blank">clinicaltrials:NCT03183128</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The purpose of this study is to demonstrate the superiority of SER-109 vs placebo to reduce recurrence of CDI as determined by a toxin assay in adults up to 8 weeks after initiation of treatment."</div>
                
                
                <div class="evidence-explanation">Clinical trial objective directly targets recurrence prevention after standard therapy.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1177/20503121241274192" target="_blank">DOI:10.1177/20503121241274192</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Compared with placebo, VOS following standard-of-care antibiotics for CDI significantly reduced risk of recurrence at 8 weeks (relative risk, 0.32 (95% CI: 0.18-0.58); p &lt; 0.001; number needed to treat: 4) with a tolerable safety profile; rCDI rates remained low through 24 weeks."</div>
                
                
                <div class="evidence-explanation">Review synthesis reports strong recurrence-prevention efficacy for the SER-109 program.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box clinical-trial-box">
                <div class="item-name">
                    NCT03244644
                    
                    <span class="tag tag-phase">PHASE_III</span>
                    
                    
                    <span class="tag tag-status">COMPLETED</span>
                    
                </div>
                
                <div class="item-desc">PUNCH CD3 trial evaluating RBX2660 microbiota suspension versus placebo for prevention of recurrent CDI after antibiotic treatment.
</div>
                
                
                <div class="item-meta">
                    <strong style="font-size: 0.8rem; color: #6b21a8;">Target Phenotypes:</strong>
                    
                    <span class="tag" style="background: #ede9fe; color: #6b21a8; font-size: 0.8rem;">
                        Diarrhea
                        
                        <a href="http://purl.obolibrary.org/obo/HP_0002014" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://clinicaltrials.gov/study/NCT03244644" target="_blank">clinicaltrials:NCT03244644</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"This is a prospective, multicenter, randomized, double-blinded, placebo-controlled Phase 3 study of a microbiota suspension of intestinal microbes."</div>
                
                
                <div class="evidence-explanation">Trial registry confirms phase, design, and microbiota-based intervention strategy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box clinical-trial-box">
                <div class="item-name">
                    NCT01241552
                    
                    <span class="tag tag-phase">PHASE_III</span>
                    
                    
                    <span class="tag tag-status">COMPLETED</span>
                    
                </div>
                
                <div class="item-desc">MODIFY I trial evaluating anti-toxin monoclonal antibodies added to standard-of-care antibiotics to reduce CDI recurrence.
</div>
                
                
                <div class="item-meta">
                    <strong style="font-size: 0.8rem; color: #6b21a8;">Target Phenotypes:</strong>
                    
                    <span class="tag" style="background: #ede9fe; color: #6b21a8; font-size: 0.8rem;">
                        Diarrhea
                        
                        <a href="http://purl.obolibrary.org/obo/HP_0002014" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                    <span class="tag" style="background: #ede9fe; color: #6b21a8; font-size: 0.8rem;">
                        Fever
                        
                        <a href="http://purl.obolibrary.org/obo/HP_0001945" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://clinicaltrials.gov/study/NCT01241552" target="_blank">clinicaltrials:NCT01241552</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"treatment with MK-3415A in addition to standard of care (SOC) antibiotic therapy will decrease Clostridium difficile infection (CDI) recurrence as compared to treatment with MK-6072 or MK-3415"</div>
                
                
                <div class="evidence-explanation">Registry endpoint explicitly targets recurrence reduction using anti-toxin monoclonal therapy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Clostridioides difficile Infection
creation_date: &#39;2025-12-19T01:18:09Z&#39;
updated_date: &#39;2026-02-19T17:30:29Z&#39;
category: Infectious
disease_term:
  preferred_term: Clostridium difficile colitis
  term:
    id: MONDO:0000705
    label: Clostridium difficile colitis
parents:
- Infectious colitis
- Healthcare-associated infections
synonyms:
- C. difficile infection
- CDI
- Clostridium difficile infection
- Clostridium difficile colitis
has_subtypes:
- name: Acute Clostridioides difficile infection
  description: &gt;
    First-episode CDI with manifestations ranging from uncomplicated antibiotic-associated
    diarrhea to severe fulminant colitis.
  evidence:
  - reference: PMID:28613708
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      C difficile infections can range from an asymptomatic carrier to diarrhea,
      progressing to severe conditions such as pseudomembranous colitis and toxic
      megacolon with septic shock, often resulting in a high mortality rate.
    explanation: Supports a broad acute disease spectrum from mild to fulminant presentation.
- name: Recurrent Clostridioides difficile infection
  description: &gt;
    Recurrent CDI (rCDI) following initial treatment, typically occurring in the
    early post-antibiotic period and representing a major clinical subtype.
  subtype_frequency: up to 25%
  evidence:
  - reference: DOI:10.1177/20503121241274192
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      Up to 25% of patients with an initial CDI episode will experience recurrent CDI
      (rCDI), which most commonly occurs in the first 8 weeks following antibiotic
      therapy.
    explanation: Provides explicit frequency and timing evidence for the recurrent subtype.
- name: Non-colitic C. difficile infection (carrier state or diarrheal disease)
  description: &gt;
    Infection states without overt colitis, including asymptomatic carriage and
    diarrheal presentations that do not progress to severe colonic inflammation.
  evidence:
  - reference: PMID:28613708
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      C difficile infections can range from an asymptomatic carrier to diarrhea,
      progressing to severe conditions such as pseudomembranous colitis and toxic
      megacolon with septic shock, often resulting in a high mortality rate.
    explanation: Explicitly supports CDI forms that precede or occur without severe colitis.
classifications:
  harrisons_chapter:
  - classification_value: infectious disease
    evidence:
    - reference: PMID:39204246
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: &gt;-
        Clostridioides difficile is the main causative agent of antibiotic-associated
        diarrhea (AAD) in hospitals in the developed world.
      explanation: Supports classification of CDI within infectious diseases.
  - classification_value: bacterial infectious disease
    evidence:
    - reference: PMID:28613708
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: &gt;-
        Clostridioides difficile, formerly Clostridium difficile, is a gram-positive and
        spore-forming bacterium.
      explanation: Supports bacterial infectious disease classification of CDI.
prevalence:
- population: Adults after an initial CDI episode
  percentage: 25
  evidence:
  - reference: DOI:10.1177/20503121241274192
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      Up to 25% of patients with an initial CDI episode will experience recurrent CDI
      (rCDI), which most commonly occurs in the first 8 weeks following antibiotic
      therapy.
    explanation: Recent systematic review quantifies the high short-term recurrence burden after first CDI.
- population: Hospitalized patients (United States, annual burden)
  evidence:
  - reference: DOI:10.1177/20503121241274192
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      Clostridioides difficile infection (CDI) has been linked to over 200,000 cases of
      illness in hospitalized patients and over 20,000 deaths annually.
    explanation: Provides contemporary burden estimates for severe and healthcare-associated CDI.
infectious_agent:
- name: Clostridioides difficile
  description: &gt;
    Anaerobic, spore-forming Gram-positive bacillus and the principal etiologic
    agent of antibiotic-associated colitis and healthcare-associated diarrhea.
  infectious_agent_term:
    preferred_term: Clostridioides difficile
    term:
      id: NCBITaxon:1496
      label: Clostridioides difficile
  evidence:
  - reference: PMID:39204246
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      Clostridioides difficile is the main causative agent of antibiotic-associated
      diarrhea (AAD) in hospitals in the developed world.
    explanation: Directly establishes C. difficile as the core infectious agent for CDI.
pathophysiology:
- name: Antibiotic-Induced Microbial Depletion
  description: &gt;
    Broad-spectrum antibiotics (especially fluoroquinolones, clindamycin,
    cephalosporins) cause indiscriminate killing of gut commensals, dramatically
    reducing microbial diversity and biomass. This creates ecological opportunity
    for C. difficile colonization.
  locations:
  - preferred_term: colon
    term:
      id: UBERON:0001155
      label: colon
  downstream:
  - target: Loss of Colonization Resistance
    description: Depleted microbiota cannot compete with C. difficile
    evidence:
    - reference: PMID:26185088
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: &gt;-
        Upon disturbance of the microbiota, CR can be transiently disrupted, and pathogens
        can gain the opportunity to grow to high levels.
      explanation: Antibiotic disruption weakens colonization resistance, opening ecological space for pathogens.
  - target: Loss of Secondary Bile Acid Production
    description: Depletion of bile acid 7Œ±-dehydroxylating bacteria
    evidence:
    - reference: PMID:39377587
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: &gt;-
        We show changes in the abundance of many lipids, specifically a decrease in
        acylcarnitines post-FMT, and a shift from conjugated bile acids pre-FMT to
        deconjugated secondary bile acids post-FMT.
      explanation: Microbiome disruption alters bile-acid pools; restoration of secondary bile acids is a mechanistic signal of recovery.
  evidence:
  - reference: PMID:28613708
    supports: SUPPORT
    snippet: &#34;The most significant risk factor for C difficile infection is broad-spectrum antibiotics. Patients can be colonized with C difficile without symptoms, but antibiotic use disturbs the balance of gut flora, enabling C difficile overgrowth and infection.&#34;
    explanation: StatPearls notes antibiotic-driven dysbiosis allows C. difficile overgrowth in the colon.

- name: Loss of Colonization Resistance
  description: &gt;
    The healthy microbiome normally prevents C. difficile colonization through
    multiple mechanisms: nutrient competition (especially for proline, amino acids),
    niche exclusion, and production of bacteriocins and antimicrobial peptides.
    Antibiotic disruption removes these competitive barriers.
  notes: &gt;
    Metagenomics studies consistently show CDI patients have depleted Lachnospiraceae,
    Ruminococcaceae, and Collinsella spp. compared to controls. BugSigDB signatures
    for CDI-related studies confirm depletion of these protective taxa. The Lachnospiraceae
    member C. scindens is particularly important for bile acid-mediated resistance.
  downstream:
  - target: C. difficile Germination and Expansion
    description: Without competitive exclusion, C. diff spores germinate and vegetative cells proliferate
    evidence:
    - reference: PMID:26185088
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: &gt;-
        Upon disturbance of the microbiota, CR can be transiently disrupted, and
        pathogens can gain the opportunity to grow to high levels.
      explanation: Loss of colonization resistance permits pathogen expansion, including C. difficile.
  evidence:
  - reference: PMID:26185088
    supports: SUPPORT
    snippet: &#34;A general feature of a normal, healthy gut microbiota can generate conditions in the gut that disfavor colonization of enteric pathogens. This is termed colonization-resistance (CR). Upon disturbance of the microbiota, CR can be transiently disrupted, and pathogens can gain the opportunity to grow to high levels.&#34;
    explanation: Review describes colonization resistance as a key protective function lost during antibiotic-induced dysbiosis.
  - reference: PMID:40366862
    supports: PARTIAL
    snippet: &#34;The gut microbiota in the Control group showed higher Chao1 index (p &lt; 0.05)... Collinsella_aerofaciens, Collinsella_sp_4_8_47FAA, Collinsella_tanakaei and Collinsella_sp_CAG_166 were enriched in Control.&#34;
    explanation: Metagenomic study confirms CDI patients have reduced diversity and depletion of protective Collinsella species compared to healthy controls.

- name: Loss of Secondary Bile Acid Production
  description: &gt;
    Loss of bile acid 7Œ±-dehydroxylating bacteria (Clostridium scindens,
    C. hylemonae, and related taxa) prevents conversion of primary bile acids
    (cholate, chenodeoxycholate) to secondary bile acids (deoxycholate,
    lithocholate). Primary bile acids promote C. difficile spore germination;
    secondary bile acids inhibit both germination and vegetative growth.
  notes: &gt;
    The bai (bile acid-inducible) operon encodes the 7Œ±-dehydroxylation pathway.
    ~2mM deoxycholate is sufficient to inhibit C. difficile growth in vitro.
  downstream:
  - target: C. difficile Germination and Expansion
    description: Elevated primary bile acids and depleted secondary bile acids favor spore germination
    evidence:
    - reference: PMID:37126691
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: &gt;-
        Intestinal bile acids play an essential role in the Clostridioides difficile
        lifecycle having been shown in vitro to modulate various aspects of
        pathogenesis, including spore germination, vegetative growth, and more recently
        the action of the primary virulence determinant, TcdB.
      explanation: Bile-acid composition directly regulates CDI establishment and early growth dynamics.
  evidence:
  - reference: PMID:32179626
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: &#34;Inhibition of C. difficile by commensals correlated with the efficient conversion of cholate to deoxycholate, a secondary bile acid that inhibits C. difficile germination, growth, and toxin production.&#34;
    explanation: Study shows bile acid conversion by bai operon-carrying bacteria is key to C. difficile inhibition.
  - reference: PMID:28066726
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: &#34;Amendment of Oligo-MM12 with C. scindens normalized the large intestinal bile acid composition by reconstituting 7Œ±-dehydroxylation. These changes had only minor effects on the composition of the native Oligo-MM12, but significantly decreased early large intestinal C. difficile colonization and pathogenesis.&#34;
    explanation: Gnotobiotic mouse study demonstrates C. scindens provides colonization resistance through bile acid metabolism.

- name: Bile Acid-Mediated TcdB Buffering Failure
  description: &gt;
    Intestinal bile acids can directly buffer TcdB cytotoxicity. When bile-acid
    buffering is reduced or toxin burden is high, this protection is overcome and
    toxin-mediated epithelial injury proceeds.
  downstream:
  - target: Epithelial Cell Death and Barrier Disruption
    description: Insufficient bile-acid buffering increases effective TcdB intoxication at the mucosa
    evidence:
    - reference: PMID:37126691
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: &gt;-
        We show that protection, however, is surmountable and can be overcome at higher
        doses of TcdB-typical to those seen during severe C. difficile
        infection-suggesting that the protective properties of intestinal bile acids are
        operant primarily under low to moderate toxin levels.
      explanation: Demonstrates a mechanistic threshold where bile-acid protection fails and toxin injury dominates.
  evidence:
  - reference: PMID:37126691
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: &gt;-
      Small molecules extracted from the lumenal contents of the small intestine,
      cecum, colon, and feces were found to inhibit TcdB in accordance with the
      differential amounts of total bile acids in each compartment.
    explanation: Supports direct bile-acid inhibition of TcdB as a mechanistic modifier of severity.

- name: C. difficile Germination and Expansion
  description: &gt;
    C. difficile spores germinate in the favorable environment created by
    antibiotic disruption: available nutrients (especially proline), primary
    bile acids, and lack of competition. Vegetative cells proliferate to high
    density, occupying the ecological niche vacated by commensals.
  downstream:
  - target: Toxin Production (TcdA/TcdB)
    description: Vegetative C. difficile produces toxins A and B during stationary phase
    evidence:
    - reference: PMID:39298531
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: &gt;-
        Besides producing the main virulence factors, toxin A (TcdA) and toxin B
        (TcdB), many of the common clinical strains encode the C. difficile transferase
        (CDT) binary toxin.
      explanation: Confirms vegetative C. difficile strains produce canonical toxin virulence programs.
  evidence:
  - reference: PMID:28613708
    supports: SUPPORT
    snippet: &#34;Patients can be colonized with C difficile without symptoms, but antibiotic use disturbs the balance of gut flora, enabling C difficile overgrowth and infection.&#34;
    explanation: Antibiotic-disrupted environment permits C. difficile overgrowth from spore to vegetative form.

- name: Toxin Production (TcdA/TcdB)
  description: &gt;
    C. difficile secretes two large clostridial glucosylating toxins: TcdA
    (enterotoxin, 308 kDa) and TcdB (cytotoxin, 270 kDa). Both are
    glucosyltransferases that inactivate Rho family GTPases (Rho, Rac, Cdc42)
    by monoglucosylation of a critical threonine residue, disrupting the
    actin cytoskeleton.
  biological_processes:
  - preferred_term: Pathogenesis
    term:
      id: GO:0009405
      label: pathogenesis
  downstream:
  - target: Epithelial Cell Death and Barrier Disruption
    description: Toxins cause cytoskeletal collapse and cell death
    evidence:
    - reference: DOI:10.3390/microorganisms12051004
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: &gt;-
        These toxins disrupt colonic epithelial barrier integrity, and induce
        inflammation and cellular damage, leading to CDI symptoms.
      explanation: Toxin biology directly explains epithelial barrier collapse and downstream tissue injury.
  - target: Neutrophil Recruitment and Inflammation
    description: Toxins trigger IL-8 release and massive neutrophil influx
    evidence:
    - reference: DOI:10.3390/microorganisms12051004
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: &gt;-
        These toxins disrupt colonic epithelial barrier integrity, and induce
        inflammation and cellular damage, leading to CDI symptoms.
      explanation: The same toxin-driven injury initiates the inflammatory cascade and leukocyte recruitment.
  - target: Binary Toxin (CDT)-Associated Inflammatory Signaling
    description: CDT in toxin-positive strains further amplifies inflammatory injury programs
    evidence:
    - reference: DOI:10.3390/microorganisms12051004
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: &gt;-
        Certain strains produce an additional toxin, the C. difficile transferase
        (CDT), which further enhances the virulence and pathogenicity of C. difficile.
      explanation: Establishes CDT as an additional inflammatory virulence amplifier.
  evidence:
  - reference: PMID:15831824
    supports: SUPPORT
    snippet: &#34;Following expression and release from the bacterium, TcdA and TcdB translocate to the cytosol of target cells and inactivate small GTP-binding proteins, which include Rho, Rac, and Cdc42. Inactivation of these substrates occurs through monoglucosylation of a single reactive threonine.&#34;
    explanation: Comprehensive review details the molecular mechanism of toxin action on Rho GTPases.
  - reference: PMID:34837014
    supports: SUPPORT
    snippet: &#34;The bacterium produces up to three toxins, which are considered the major virulence factors in C. difficile infection. These toxins promote inflammation, tissue damage and diarrhoea.&#34;
    explanation: Review confirms toxins as major virulence factors causing disease pathology.

- name: Epithelial Cell Death and Barrier Disruption
  description: &gt;
    Toxin-mediated Rho GTPase inactivation causes actin cytoskeleton
    condensation, loss of cell-cell junctions, and epithelial cell rounding
    followed by death. This creates gaps in the epithelial barrier, exposing
    the lamina propria to luminal contents.
  cell_types:
  - preferred_term: Colonic Epithelial Cell
    term:
      id: CL:0011108
      label: colon epithelial cell
  downstream:
  - target: Pseudomembranous Colitis
    description: Epithelial destruction with inflammatory exudate forms pseudomembranes
    evidence:
    - reference: PMID:39204246
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: &gt;-
        C. difficile infection (CDI) shows a large range of symptoms, from mild
        diarrhea to severe manifestations such as pseudomembranous colitis.
      explanation: Connects severe epithelial injury in CDI to the pseudomembranous colitis endpoint.
  evidence:
  - reference: PMID:15831824
    supports: SUPPORT
    snippet: &#34;By glucosylating small GTPases, TcdA and TcdB cause actin condensation and cell rounding, which is followed by death of the cell.&#34;
    explanation: Review describes the cellular consequences of toxin-mediated GTPase inactivation.

- name: Binary Toxin (CDT)-Associated Inflammatory Signaling
  description: &gt;
    In CDT-positive strains, the binary toxin axis can activate inflammasome-linked
    inflammatory pathways in myeloid cells and increase early disease severity.
  downstream:
  - target: Neutrophil Recruitment and Inflammation
    description: CDT-driven inflammasome signaling amplifies cytokine-mediated inflammatory recruitment
    evidence:
    - reference: PMID:39298531
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: &gt;-
        Here, we show that CDT does not prime but instead activates the inflammasome in
        bone marrow-derived dendritic cells (BMDCs).
      explanation: Provides direct experimental evidence that CDT can trigger pro-inflammatory inflammasome pathways.
  evidence:
  - reference: PMID:39298531
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: &gt;-
      Besides producing the main virulence factors, toxin A (TcdA) and toxin B
      (TcdB), many of the common clinical strains encode the C. difficile transferase
      (CDT) binary toxin.
    explanation: Documents the presence of CDT among common clinical strains and supports including a CDT-specific mechanism node.

- name: Neutrophil Recruitment and Inflammation
  description: &gt;
    TcdA triggers IL-8 and other chemokine release from epithelial cells,
    causing massive neutrophil influx into the colonic mucosa. Neutrophils
    form the characteristic &#34;volcano lesions&#34; and contribute to tissue damage
    through degranulation, reactive oxygen species, and NET formation.
  cell_types:
  - preferred_term: Neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  biological_processes:
  - preferred_term: Inflammatory Response
    term:
      id: GO:0006954
      label: inflammatory response
  downstream:
  - target: Pseudomembranous Colitis
    description: Neutrophils form the inflammatory core of pseudomembranes
    evidence:
    - reference: PMID:39204246
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: &gt;-
        C. difficile infection (CDI) shows a large range of symptoms, from mild
        diarrhea to severe manifestations such as pseudomembranous colitis.
      explanation: Severe inflammatory CDI culminates in pseudomembranous colitis.
  evidence:
  - reference: PMID:15831824
    supports: SUPPORT
    snippet: &#34;Furthermore, there have been major advances in defining the role of these toxins in modulating the inflammatory events involving the disruption of cell junctions, neuronal activation, cytokine production, and infiltration by polymorphonuclear cells.&#34;
    explanation: Review details toxin-induced inflammatory cascade including neutrophil recruitment.

- name: Pseudomembranous Colitis
  description: &gt;
    Characteristic raised yellow-white plaques on colonic mucosa composed of
    fibrin, mucus, neutrophils, and cellular debris overlying areas of
    epithelial necrosis. Represents severe C. difficile infection with high
    morbidity. Fluid secretion and diarrhea result from barrier loss and
    inflammation.
  locations:
  - preferred_term: colon
    term:
      id: UBERON:0001155
      label: colon
  evidence:
  - reference: PMID:34837014
    supports: PARTIAL
    snippet: &#34;These toxins promote inflammation, tissue damage and diarrhoea.&#34;
    explanation: Toxin activity drives the pseudomembrane-associated inflammation and diarrheal fluid loss that characterize severe CDI.
phenotypes:
- name: Diarrhea
  description: Watery diarrhea, often foul-smelling, is the hallmark symptom.
  phenotype_term:
    preferred_term: Diarrhea
    term:
      id: HP:0002014
      label: Diarrhea
  evidence:
  - reference: PMID:28613708
    supports: SUPPORT
    snippet: This obligate anaerobic bacillus is recognized for its ability to produce toxins and is the leading cause of antibiotic-associated diarrhea worldwide.
    explanation: StatPearls review states CDI is the leading cause of antibiotic-associated diarrhea.
- name: Abdominal pain
  description: Cramping abdominal pain accompanying diarrhea.
  phenotype_term:
    preferred_term: Abdominal pain
    term:
      id: HP:0002027
      label: Abdominal pain
  evidence:
  - reference: PMID:37004449
    supports: PARTIAL
    snippet: A 40 years old male patient presented with abdominal pain and diarrhea of 10 days duration after he was diagnosed and managed as a case of Clostridium Difficile infection and amebiasis.
    explanation: Case report notes abdominal pain with CDI presentation.
- name: Fever
  description: Systemic inflammatory response to infection.
  phenotype_term:
    preferred_term: Fever
    term:
      id: HP:0001945
      label: Fever
  evidence:
  - reference: PMID:33402156
    supports: PARTIAL
    snippet: A 53-year-old Caucasian male presented to the emergency room for two days of lower abdominal pain associated with nausea, non-bilious vomiting, and subjective fevers.
    explanation: CDI case report documents fever accompanying infection.
- name: Nausea
  description: Nausea can accompany CDI, particularly in more severe inflammatory presentations.
  phenotype_term:
    preferred_term: Nausea
    term:
      id: HP:0002018
      label: Nausea
  evidence:
  - reference: PMID:33402156
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: A 53-year-old Caucasian male presented to the emergency room for two days of lower abdominal pain associated with nausea, non-bilious vomiting, and subjective fevers.
    explanation: Case report documents nausea among presenting symptoms in laboratory-confirmed CDI.
- name: Vomiting
  description: Emesis may co-occur with abdominal pain and diarrhea in CDI.
  phenotype_term:
    preferred_term: Vomiting
    term:
      id: HP:0002013
      label: Vomiting
  evidence:
  - reference: PMID:33402156
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: A 53-year-old Caucasian male presented to the emergency room for two days of lower abdominal pain associated with nausea, non-bilious vomiting, and subjective fevers.
    explanation: Case report documents vomiting as part of CDI clinical presentation.
- name: Pseudomembranous colitis
  description: Severe inflammatory colitis phenotype marked by pseudomembrane formation.
  phenotype_term:
    preferred_term: Colitis
    term:
      id: HP:0002583
      label: Colitis
  evidence:
  - reference: PMID:28613708
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      C difficile infections can range from an asymptomatic carrier to diarrhea,
      progressing to severe conditions such as pseudomembranous colitis and toxic
      megacolon with septic shock, often resulting in a high mortality rate.
    explanation: Explicitly identifies pseudomembranous colitis as a severe CDI manifestation.
- name: Toxic megacolon
  description: Life-threatening colonic dilation and systemic toxicity in severe CDI.
  phenotype_term:
    preferred_term: Megacolon
    term:
      id: HP:6000852
      label: Megacolon
  evidence:
  - reference: PMID:28613708
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      C difficile infections can range from an asymptomatic carrier to diarrhea,
      progressing to severe conditions such as pseudomembranous colitis and toxic
      megacolon with septic shock, often resulting in a high mortality rate.
    explanation: Supports toxic megacolon as a severe, high-risk complication of CDI.
- name: Septic shock
  description: Severe systemic shock state that can complicate fulminant CDI.
  phenotype_term:
    preferred_term: Shock
    term:
      id: HP:0031273
      label: Shock
  evidence:
  - reference: PMID:28613708
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      C difficile infections can range from an asymptomatic carrier to diarrhea,
      progressing to severe conditions such as pseudomembranous colitis and toxic
      megacolon with septic shock, often resulting in a high mortality rate.
    explanation: Supports septic shock as a life-threatening complication in severe CDI.
treatments:
- name: Vancomycin
  description: Oral vancomycin is first-line treatment for C. difficile infection.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    qualifiers:
    - predicate:
        preferred_term: route of administration
        term:
          id: NCIT:C38114
          label: Route of Administration
      value:
        preferred_term: oral route of administration
        term:
          id: NCIT:C38288
          label: Oral Route of Administration
    - predicate:
        preferred_term: therapeutic agent
        term:
          id: NCIT:C2259
          label: Therapeutic Agent
      value:
        preferred_term: vancomycin
        term:
          id: NCIT:C288
          label: vancomycin
  evidence:
  - reference: PMID:38508330
    supports: SUPPORT
    snippet: Effective infection management requires appropriate interpretation of diagnostic tests, as well as the use of vancomycin and fidaxomicin as first-line treatment.
    explanation: Clinical review lists oral vancomycin among first-line agents for CDI management.
- name: Fidaxomicin
  description: Alternative antibiotic with lower recurrence rates.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    qualifiers:
    - predicate:
        preferred_term: route of administration
        term:
          id: NCIT:C38114
          label: Route of Administration
      value:
        preferred_term: oral route of administration
        term:
          id: NCIT:C38288
          label: Oral Route of Administration
    - predicate:
        preferred_term: therapeutic agent
        term:
          id: NCIT:C2259
          label: Therapeutic Agent
      value:
        preferred_term: fidaxomicin
        term:
          id: NCIT:C95509
          label: fidaxomicin
  evidence:
  - reference: PMID:38726585
    supports: SUPPORT
    snippet: IDSA/SHEA shifted its preference for initial treatment to fidaxomicin over vancomycin and metronidazole due to its lower recurrence rate.
    explanation: Guideline update highlights fidaxomicin as preferred initial therapy because of reduced recurrence.
  - reference: PMID:39282548
    supports: SUPPORT
    snippet: Management of CDI has evolved, with fidaxomicin emerging as a superior treatment option over vancomycin for initial and recurrent infections due to its reduction of recurrence rate.
    explanation: Recent review reinforces fidaxomicin&#39;s superiority to vancomycin for initial and recurrent CDI.
- name: Fecal microbiota transplantation
  description: Restoration of normal gut microbiota for recurrent infections.
  treatment_term:
    preferred_term: fecal microbiota transplantation
    term:
      id: MAXO:0000748
      label: fecal microbiota transplantation
    qualifiers:
    - predicate:
        preferred_term: clinical course
        term:
          id: NCIT:C28008
          label: Clinical Course
      value:
        preferred_term: recurrent disease
        term:
          id: MONDO:0700096
          label: recurrent disease
  evidence:
  - reference: PMID:38508330
    supports: SUPPORT
    snippet: Novel treatments such as Bezlotoxumab, fecal microbiota transplant, and live biotherapeutic products are proven effective in recurrent C. difficile infection and address dysbiosis.
    explanation: Review notes FMT as effective for recurrent CDI in restoring microbiota.
  - reference: PMID:39282548
    supports: SUPPORT
    snippet: Faecal microbiota transplantation (FMT) is effective for recurrent CDI, restoring gut eubiosis.
    explanation: Update article explicitly states FMT effectiveness for recurrent CDI by reestablishing gut balance.
- name: Bezlotoxumab
  description: Monoclonal antibody against toxin B to prevent CDI recurrence when added to standard therapy.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    qualifiers:
    - predicate:
        preferred_term: therapeutic agent
        term:
          id: NCIT:C2259
          label: Therapeutic Agent
      value:
        preferred_term: bezlotoxumab
        term:
          id: NCIT:C121379
          label: Bezlotoxumab
  evidence:
  - reference: PMID:39282548
    supports: SUPPORT
    snippet: Bezlotoxumab, a monoclonal antibody against C. difficile toxin B, has shown promise in reducing recurrence rates.
    explanation: Review notes bezlotoxumab reduces CDI recurrence when used adjunctively with standard antibiotics.
- name: Loop ileostomy with colonic lavage
  description: Organ-preserving surgical approach for fulminant CDI when medical therapy fails.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
  evidence:
  - reference: PMID:39650985
    supports: PARTIAL
    snippet: In cases where pharmacological management has been ineffective, fecal microbiota transplantation and surgical intervention demonstrated success.
    explanation: Case report highlights loop ileostomy with lavage as a surgical option after failed pharmacologic therapy in fulminant CDI.
differential_diagnoses:
- name: Ulcerative colitis
  description: Chronic immune-mediated colitis that can flare with bloody diarrhea and may coexist with CDI.
  distinguishing_features:
  - Continuous colonic inflammation from rectum proximally on endoscopy.
  - Bloody mucus stools and chronic course with flares.
  - Histology shows crypt architectural distortion and chronic inflammatory infiltrate.
  disease_term:
    preferred_term: ulcerative colitis
    term:
      id: MONDO:0005101
      label: ulcerative colitis
  evidence:
  - reference: PMID:38335423
    supports: SUPPORT
    snippet: This case underscores the diagnosis of severe UC through colonoscopy and colonic biopsy, along with the supplementary identification of a positive result for Clostridioides difficile in the fecal sample.
    explanation: Report highlights overlapping presentation of UC flare with concurrent CDI.
- name: Lymphocytic colitis
  description: Microscopic colitis subtype causing chronic watery diarrhea that can mimic or coexist with CDI.
  distinguishing_features:
  - Chronic watery diarrhea with normal endoscopic appearance.
  - Biopsy reveals increased intraepithelial lymphocytes without ulceration.
  disease_term:
    preferred_term: lymphocytic colitis
    term:
      id: MONDO:0000704
      label: lymphocytic colitis
  evidence:
  - reference: PMID:38313897
    supports: SUPPORT
    snippet: Persistent watery diarrhea and was diagnosed with lymphocytic colitis in the setting of a concomitant C. difficile infection.
    explanation: Case shows lymphocytic colitis presenting with CDI-like diarrhea.
- name: Ischemic colitis
  description: Colonic ischemia presenting with acute abdominal pain and diarrhea that can be confused with infectious colitis.
  distinguishing_features:
  - Sudden crampy abdominal pain with segmental ischemic changes on imaging/endoscopy.
  - Often hematochezia and disproportionate pain relative to diarrhea volume.
  disease_term:
    preferred_term: ischemic colitis
    term:
      id: MONDO:0000701
      label: ischemic colitis
  evidence:
  - reference: PMID:37004449
    supports: SUPPORT
    snippet: A 40 years old male patient presented with abdominal pain and diarrhea of 10 days duration after he was diagnosed and managed as a case of Clostridium Difficile infection and amebiasis; computed tomography angiography revealed a vascular malformation ... he underwent Hartmann&#39;s procedure due to colonic ischemia.
    explanation: Case documents ischemic colitis occurring in the context of CDI symptoms.
- name: Strongyloidiasis hyperinfection
  description: Parasitic hyperinfection that can present with diarrhea and mimic severe CDI in immunosuppressed hosts.
  distinguishing_features:
  - Occurs in immunosuppressed patients (e.g., prolonged steroids) with disseminated larvae.
  - Larvae detectable in stool, sputum, or bronchoalveolar lavage; eosinophilia may be absent.
  disease_term:
    preferred_term: strongyloidiasis
    term:
      id: MONDO:0005974
      label: strongyloidiasis
  evidence:
  - reference: PMID:35181536
    supports: SUPPORT
    snippet: We describe a fatal case of S. stercoralis hyperinfection ... presenting with diarrhea along with Clostridium difficile colitis after the use of a prolonged course of steroids.
    explanation: Report shows Strongyloides hyperinfection mimicking CDI in steroid-treated patient.
- name: Acute appendicitis
  description: Extraintestinal manifestation with right lower quadrant pain that can coexist with or be mistaken for CDI.
  distinguishing_features:
  - Localized right lower quadrant tenderness with rebound/guarding.
  - CT shows appendiceal enlargement and wall thickening; diarrhea often absent or minimal.
  disease_term:
    preferred_term: appendicitis
    term:
      id: MONDO:0005649
      label: appendicitis
  evidence:
  - reference: PMID:33402156
    supports: SUPPORT
    snippet: Repeat CT of the abdomen and pelvis with contrast (Fig. 1) was performed which showed progression of his colitis, now extending from the cecum to the rectum as well as findings concerning for appendicitis as seen on the prior CT scan. C. difficile testing was positive for which the patient was started on oral vancomycin.
    explanation: Case report documents appendicitis identified alongside CDI with CT progression guiding management.
transmission:
- name: Healthcare-associated environmental spore transmission
  description: &gt;
    Transmission in healthcare settings is driven by environmentally persistent
    spores and exposure to contaminated hospital surfaces or equipment.
  evidence:
  - reference: PMID:28613708
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      Contaminated surfaces and medical equipment in healthcare facilities can become
      reservoirs for C difficile spores, potentially transmitting to patients if proper
      cleaning protocols are not routinely implemented.
    explanation: Supports environmental fomite-mediated spread in healthcare settings.
- name: Transmission from symptomatic and asymptomatic carriers
  description: &gt;
    Both symptomatic cases and asymptomatic colonized individuals can serve as
    transmission sources, sustaining CDI spread in both hospitals and community settings.
  evidence:
  - reference: PMID:39204246
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      Both infected patients and asymptomatic colonized individuals represent
      important transmission sources of C. difficile.
    explanation: Supports person-to-person and reservoir-mediated transmission dynamics.
diagnosis:
- name: Clinical interpretation of stool diagnostic testing
  description: &gt;
    CDI diagnosis requires integrating compatible clinical features (typically new
    diarrhea) with appropriate interpretation of stool diagnostic assays.
  evidence:
  - reference: PMID:38508330
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      Effective infection management requires appropriate interpretation of diagnostic
      tests, as well as the use of vancomycin and fidaxomicin as first-line treatment.
    explanation: Recent clinical review emphasizes diagnostic stewardship as central to CDI management.
  - reference: PMID:29462280
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      This guideline updates recommendations regarding epidemiology, diagnosis,
      treatment, infection prevention, and environmental management.
    explanation: IDSA/SHEA guideline confirms diagnosis as a core standardized component of CDI care.
datasets:
- accession: sra:PRJNA1055134
  title: Metagenomic, metabolomic, and lipidomic shifts associated with fecal microbiota transplantation for recurrent CDI
  description: &gt;-
    Longitudinal stool multi-omics dataset from recurrent CDI patients sampled
    before and after successful FMT, used to profile microbiome, lipidome, and
    metabolome restructuring associated with recurrence prevention.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: METABOLOMICS
  sample_count: 14
  conditions:
  - recurrent CDI pre-FMT
  - recurrent CDI post-FMT
  publication: PMID:39377587
  evidence:
  - reference: PMID:39377587
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      Here, we use longitudinal stool samples collected from patients undergoing FMT
      to evaluate intra-individual changes in the microbiome, metabolome, and lipidome
      after successful FMTs relative to their baselines pre-FMT.
    explanation: Describes the core study design and rationale represented in this rCDI dataset.
  notes: &gt;
    Public sequencing reads are deposited under BioProject PRJNA1055134
    (reported in the article&#39;s data-availability section).
clinical_trials:
- name: NCT03183128
  phase: PHASE_III
  status: COMPLETED
  description: &gt;
    ECOSPOR III trial evaluating oral SER-109 versus placebo after standard-of-care
    antibiotics to prevent recurrent CDI.
  target_phenotypes:
  - preferred_term: Diarrhea
    term:
      id: HP:0002014
      label: Diarrhea
  evidence:
  - reference: clinicaltrials:NCT03183128
    supports: SUPPORT
    snippet: &gt;-
      The purpose of this study is to demonstrate the superiority of SER-109 vs placebo
      to reduce recurrence of CDI as determined by a toxin assay in adults up to 8 weeks
      after initiation of treatment.
    explanation: Clinical trial objective directly targets recurrence prevention after standard therapy.
  - reference: DOI:10.1177/20503121241274192
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      Compared with placebo, VOS following standard-of-care antibiotics for CDI
      significantly reduced risk of recurrence at 8 weeks (relative risk, 0.32 (95%
      CI: 0.18-0.58); p &lt; 0.001; number needed to treat: 4) with a tolerable safety
      profile; rCDI rates remained low through 24 weeks.
    explanation: Review synthesis reports strong recurrence-prevention efficacy for the SER-109 program.
- name: NCT03244644
  phase: PHASE_III
  status: COMPLETED
  description: &gt;
    PUNCH CD3 trial evaluating RBX2660 microbiota suspension versus placebo for
    prevention of recurrent CDI after antibiotic treatment.
  target_phenotypes:
  - preferred_term: Diarrhea
    term:
      id: HP:0002014
      label: Diarrhea
  evidence:
  - reference: clinicaltrials:NCT03244644
    supports: SUPPORT
    snippet: &gt;-
      This is a prospective, multicenter, randomized, double-blinded, placebo-controlled
      Phase 3 study of a microbiota suspension of intestinal microbes.
    explanation: Trial registry confirms phase, design, and microbiota-based intervention strategy.
- name: NCT01241552
  phase: PHASE_III
  status: COMPLETED
  description: &gt;
    MODIFY I trial evaluating anti-toxin monoclonal antibodies added to standard-of-care
    antibiotics to reduce CDI recurrence.
  target_phenotypes:
  - preferred_term: Diarrhea
    term:
      id: HP:0002014
      label: Diarrhea
  - preferred_term: Fever
    term:
      id: HP:0001945
      label: Fever
  evidence:
  - reference: clinicaltrials:NCT01241552
    supports: SUPPORT
    snippet: &gt;-
      treatment with MK-3415A in addition to standard of care (SOC) antibiotic therapy
      will decrease Clostridium difficile infection (CDI) recurrence as compared to
      treatment with MK-6072 or MK-3415
    explanation: Registry endpoint explicitly targets recurrence reduction using anti-toxin monoclonal therapy.
environmental:
- name: Healthcare facility exposure
  description: Hospital environments facilitate C. difficile spore persistence and transmission, underpinning healthcare-associated CDI.
  evidence:
  - reference: PMID:28613708
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Contaminated surfaces and medical equipment in healthcare facilities can become reservoirs for C difficile spores, potentially transmitting to patients if proper cleaning protocols are not routinely implemented.
    explanation: Review notes hospital environmental reservoirs drive healthcare-associated CDI transmission.
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Clostridioides_difficile_Infection.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
    <script>
        (function() {
            const banner = document.querySelector('.notice-banner');
            if (!banner) return;
            const dismiss = () => banner.remove();
            banner.addEventListener('click', dismiss);
            banner.addEventListener('keydown', (event) => {
                if (event.key === 'Enter' || event.key === ' ') {
                    event.preventDefault();
                    dismiss();
                }
            });
        })();
    </script>
</body>
</html>